ArticleApplied immunohistochemistry & molecular morphology : AIMM2026
Integrating Clinical and Molecular Insights: CTPS1 as a Key Biomarker of Tumor Progression and Prognosis in Colorectal Adenocarcinoma.
Article in Applied immunohistochemistry & molecular morphology : AIMM, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) remains a leading cause of global cancer-related mortality. Cytidine triphosphate synthase 1 (CTPS1) is an essential enzyme for DNA synthesis and cell cycle progression. While CTPS1 has been implicated in the pathogenesis of various malignancies, its clinical significance in colorectal adenocarcinoma remains poorly defined. This study aimed to investigate the immunohistochemical (IHC) expression of CTPS1 in colorectal adenocarcinoma and evaluate its association with clinicopathological features and survival outcomes. CTPS1 expression was assessed via IHC in 168 colorectal adenocarcinoma specimens and 142 matched adjacent non-neoplastic tissues. Statistical associations with clinicopathological parameters were analyzed using χ2 or Fisher exact tests. Progression-free survival (PFS) and disease-free survival (DFS) were estimated using the Kaplan-Meier method and compared via the log-rank test. Multivariate Cox proportional hazards regression was employed to identify independent prognostic factors. CTPS1 expression was significantly upregulated in tumour tissues compared with adjacent normal mucosa (P<0.001). High CTPS1 expression was observed in 55.4% of tumor samples and significantly correlated with advanced T stage, TNM stage, and modified Dukes staging, as well as nodal involvement, distant metastasis, tumor recurrence, and elevated serum CEA levels. Furthermore, elevated CTPS1 was associated with aggressive histologic features, including higher grade, tumor budding, poorly differentiated clusters (PDCs), and tumor deposits. Both PFS and DFS were significantly shorter in patients with high CTPS1 expression (P<0.001). Multivariate analysis confirmed that high CTPS1 expression, along with nodal status and tumor recurrence, was an independent prognostic factor for both PFS and DFS. Therefore, CTPS1 is a robust independent prognostic indicator and a marker of aggressive progression in colorectal adenocarcinoma. These findings suggest that CTPS1 is a promising biomarker for risk stratification and may guide clinical decision-making in the management of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.